Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir is a ritonavir analog optimized for HIV protease inhibition, maintaining nanomolar EC₅₀ across wild-type and resistant HIV strains (APExBIO). The compound demonstrates a Ki range of 1.3–3.6 pM and retains efficacy in the presence of human serum, outperforming ritonavir. Lopinavir’s oral bioavailability in animal models is 25% at 10 mg/kg, with Cmax of 0.8 μg/mL. Co-administration with ritonavir increases exposure (AUC) 14-fold. Lopinavir also inhibits MERS-CoV and SARS coronavirus replication at low micromolar concentrations (de Wilde et al., 2014).

Biological Rationale

Lopinavir (ABT-378) is a synthetic inhibitor of HIV-1 protease, a key enzyme required for HIV polyprotein processing and viral maturation (APExBIO). HIV protease cleaves the Gag-Pol polyprotein precursor at nine distinct sites, an essential step in the viral life cycle. Inhibition of this enzyme results in the production of immature, non-infectious virions. Lopinavir was designed as a second-generation protease inhibitor to overcome resistance mutations, particularly at the Val82 residue, which compromise ritonavir efficacy (see detailed mapping and resistance evolution; this article updates those findings by providing new quantitative benchmarks under serum conditions). Protease inhibition is central to antiretroviral therapy development and resistance profiling (expanding on mechanistic insights).

Mechanism of Action of Lopinavir

Lopinavir competitively inhibits the active site of HIV-1 protease, binding with high affinity (Ki = 1.3–3.6 pM) to both wild-type and mutant enzymes (APExBIO). The molecular structure minimizes interaction at Val82, a residue linked to ritonavir resistance. Lopinavir’s inhibitory effect prevents proteolytic cleavage of the viral polyprotein, halting maturation of viral particles. Unlike ritonavir, Lopinavir is minimally affected by serum protein binding, exhibiting a 10-fold potency advantage in human serum. The compound’s effect is quantifiable in cell-based assays at 4–52 nM and remains robust in the presence of common resistance mutations. Lopinavir also shows cross-pathogen activity, inhibiting coronavirus replication in vitro at micromolar concentrations (de Wilde et al., 2014).

Evidence & Benchmarks

• Lopinavir inhibits wild-type HIV-1 protease with Ki values of 1.3–3.6 pM under in vitro conditions (pH 7.0, 25°C) (APExBIO).
• Lopinavir retains sub-60 nM EC₅₀ in cell-based HIV protease inhibition assays, including against Val82 mutant strains (APExBIO).
• Lopinavir demonstrates 10-fold higher antiviral activity than ritonavir in the presence of human serum proteins (10% v/v, 37°C) (APExBIO).
• Oral administration in rodents (10 mg/kg) yields Cmax of 0.8 μg/mL and 25% bioavailability; plasma levels drop below quantitation limit by 6 hours (APExBIO).
• Co-administration with ritonavir increases Lopinavir AUC by 14-fold, enhancing systemic exposure (APExBIO).
• Lopinavir inhibits MERS-CoV and SARS-CoV replication in cell culture (EC₅₀: 3–8 μM, 33°C, Vero E6 cells) (de Wilde et al., 2014).
• Serum protein binding does not substantially diminish Lopinavir’s antiviral efficacy, unlike ritonavir (APExBIO).

Applications, Limits & Misconceptions

Lopinavir is widely employed in HIV protease inhibition assays, resistance evolution studies, and antiretroviral therapy development. It is suitable for cross-pathogen research, including coronavirus replication inhibition (de Wilde et al., 2014). For nuanced insights into resistance mechanism profiling, see this article. The present dossier extends the focus by offering granular pharmacokinetic and performance data under serum conditions.

Common Pitfalls or Misconceptions

• Lopinavir is not effective as monotherapy for HIV infection; resistance can emerge under suboptimal regimens.
• The compound is not water-soluble; improper formulation can compromise activity.
• It does not completely suppress viral replication in all coronavirus models; reductions are moderate and may not equate to full clinical efficacy (de Wilde et al., 2014).
• Storage above -20°C or repeated freeze-thaw cycles reduce stability and potency.
• Serum protein binding is lower than ritonavir but not absent; high-protein environments may still modulate efficacy.

Workflow Integration & Parameters

Lopinavir (SKU: A8204) is supplied as a solid with a molecular weight of 628.81 g/mol and chemical formula C₃₇H₄₈N₄O₅. It is soluble to ≥31.45 mg/mL in DMSO and ≥48.3 mg/mL in ethanol; it is insoluble in water (APExBIO). For assay preparation, dissolve Lopinavir in DMSO, filter-sterilize, and dilute into culture medium. Prepare fresh solutions for optimal activity and store aliquots at -20°C. In HIV protease inhibition assays, use concentrations in the 4–52 nM range. For in vivo work, oral dosing at 10 mg/kg achieves robust exposure; co-administration with ritonavir is recommended to boost plasma levels. For broader context on integrating Lopinavir into cross-pathogen antiviral workflows, see advanced mechanistic perspectives: this article provides more detailed practical and pharmacokinetic data for laboratory implementation.

Conclusion & Outlook

Lopinavir, as supplied by APExBIO, is a validated, high-potency HIV protease inhibitor with robust activity against wild-type and resistant strains. Its serum stability and favorable pharmacokinetic profile make it a benchmark tool for HIV infection research, resistance studies, and emerging antiviral applications. Ongoing research continues to evaluate its utility in cross-pathogen contexts, including coronavirus inhibition, but moderate efficacy in non-HIV models should be noted. For the most current lot-specific specifications and ordering, refer to the official product page.